Tetrabenazine is neuroprotective in Huntington's disease mice

Hongyu Wang1, Xi Chen1, Yuemei Li1, Tie-Shan Tang*2 and Ilya Bezprozvanny*1

Abstract

Background: Huntington’s disease (HD) is a neurodegenerative disorder caused by a polyglutamine (polyQ) expansion in Huntingtin protein (Htt). PolyQ expansion in Httexp causes selective degeneration of striatal medium spiny neurons (MSN) in HD patients. A number of previous studies suggested that dopamine signaling plays an important role in HD pathogenesis. A specific inhibitor of vesicular monoamine transporter (VMAT2) tetrabenazine (TBZ) has been recently approved by Food and Drug Administration for treatment of HD patients in the USA. TBZ acts by reducing dopaminergic input to the striatum.

Results: In previous studies we demonstrated that long-term feeding with TBZ (combined with L-Dopa) alleviated the motor deficits and reduced the striatal neuronal loss in the yeast artificial chromosome transgenic mouse model of HD (YAC128 mice). To further investigate a potential beneficial effects of TBZ for HD treatment, we here repeated TBZ evaluation in YAC128 mice starting TBZ treatment at 2 months of age (“early” TBZ group) and at 6 months of age (“late” TBZ group). In agreement with our previous studies, we found that both “early” and “late” TBZ treatments alleviated motor deficits and reduced striatal cell loss in YAC128 mice. In addition, we have been able to recapitulate and quantify depression-like symptoms in TBZ-treated mice, reminiscent of common side effects observed in HD patients taking TBZ.

Conclusions: Our results further support therapeutic value of TBZ for treatment of HD but also highlight the need to develop more specific dopamine antagonists which are less prone to side-effects.

Background

Huntington’s disease (HD) is an inherited progressive neurodegenerative disorder characterized by chorea, gradual but inexorable cognitive decline, and psychiatric disturbances [1,2]. Selective and progressive neuronal loss of the striatal medium spiny neurons (MSN) is the major feature of neuropathological changes in HD [2]. The cause of HD is an expanded polyglutamine (polyQ) in the amino-terminus of Huntingtin (Htt), a 350 kDa ubiquitously expressed cytoplasmic protein of unknown function [3]. The cellular mechanisms underlying the cause of MSN neurodegeneration in HD are not very clear, although most experimental evidences indicate that polyQ expansion in Httexp leads to a "toxic gain of function" [4]. A number of toxic functions have been assigned to Httexp, such as effects on gene transcription, formation of toxic aggregates, direct induction of apoptosis, disruption of key neuronal functions such as proteosomal or mitochondrial functions, ubiquitination pathways, axonal transport, endocytosis, synaptic transmission and calcium signaling [4-11].

In addition to glutamatergic stimulation from the cortex, the striatum is the predominant target of dopaminergic neurons that originate from the substantia nigra [12]. There is increasing evidence that the dopaminergic system may contribute to HD neuropathology [12]. Significant reduction of striatal D1 and D2 receptor density has been reported in HD patients [13-18] and HD mouse models [19-22]. High concentration of dopamine may exert direct toxic effects on striatal neurons [23-28]. Hyperdopaminergic transmission has been shown to accelerate the formation of Httexp aggregates and promote motor dysfunction in 92Q knock-in HD mouse model.
Recent evidences from our group and from other groups suggested that in HD dopaminergic and glutamatergic signaling pathways act synergistically to enhance the sensitivity of striatal neurons to mutant huntingtin toxicity via disturbed calcium homeostasis [30] and deregulated Cdk5 signaling [31]. All these studies pointed to an important role of dopaminergic pathway in HD and suggested that dopamine signaling pathway constitute a potential therapeutic target for HD treatment.

Tetrabenazine (TBZ) is a potent blocker of vesicular monoamine transporter (VMAT2). In multiple clinical trials TBZ has been shown to significantly reduce chorea symptoms in HD patients when compared with placebo group [32-35]. In our previous experiments with YAC128 mouse model of HD we demonstarted that long term administration of TBZ (in combination with L-dopa) alleviated motor deficits and reduced striatal cell loss in these mice [30]. In 2008 TBZ became the first drug officially approved by the Food and Drug administration for treatment of HD patients in the United States [35]. In clinical setting most HD patients would receive TBZ at the symptomatic stage after onset of the symptoms. To mimic clinical situation more precisely, we now repeated evaluation of TBZ in YAC128 HD mouse model and compared results obtained in the "early" treatment group (starting TBZ at 2 months, prior to onset of symptoms in YAC128 mice) and "late" treatment group (starting TBZ at 6 months, when motor symptoms start to develop in YAC128 mice). Our results demonstrated significant beneficial effects of TBZ in both "early" and "late" treatment groups of YAC128 HD mice.

**Results**

**TBZ improves motor coordination performance of YAC128 HD mice**

In the previous study we discovered that long-term oral delivery of TBZ and L-Dopa combination (starting at 2 months of age) alleviated the motor deficits in aging YAC128 mice [30]. In clinical setting most HD patients would receive TBZ at the symptomatic stage after onset of the symptoms. To compare the efficiency of "early" and "late" treatments, we now repeated TBZ trial in vivo with YAC128 mice model starting TBZ treatment early (2 months of age, "presymptomatic" mice) and late (6 months of age, "symptomatic" mice). The design of the trial is shown on Table 1. In our studies the mice from "early-TBZ" groups # 2 (YAC128) and # 5 (WT) were fed with 0.125 mg of TBZ suspended in 50 μl of PBS with 2% corn flour between 2 and 12 months of age (Table 1). The control groups #1 (YAC128) and # 4 (WT) mice were fed with 2% cornflour in PBS between 2 and 12 months of age (Table 1). The "late-TBZ" groups # 3 (YAC128) and # 6 (WT) were fed with 2% cornflour in PBS between 2 and 6 months of age and then fed with 0.125 mg of TBZ sus-pended in 50 μl of PBS with 2% corn flour between 6 and 12 months of age (Table 1). The drugs were fed orally to mice three times a week. At 12 months of age drug delivery to all 6 groups of mice was discontinued. The effectiveness of oral drug delivery was determined by 2 months of "drug dosage" trial. We found that, 30 min after feeding, TBZ concentration in blood plasma was 24 ± 7 ng/ml, that is 1.5-fold higher than our previous study [30]. Most likely increase in blood TBZ levels is due to difference in TBZ formulations used in the current and previous studies.

The motor coordination of these 6 groups of mice was assessed by "accelerated rotarod" and "beam-walk" assays at 2, 6, 9, 11 and 13 (washout) months of age as described in our previous studies [30,36]. Basal rotarod and beam-walk performance for all groups was determined before initiation of drug feeding when the mice were 2 months of age. The length of time that the mice able to stay on accelerated rotarod was used as a measure of rotarod performance. When results were analyzed, we found that the rotarod performance of WT and YAC128 mice was similar when these mice were 2 months of age (Fig 1). Consistent with the previous findings [30,37], control WT mice (fed with PBS) performed significantly better in rotarod assay (p < 0.05) than control YAC128 mice at 6, 9, 11 and 13 months of age (Fig 1). Feeding TBZ "early" to WT mice had no apparent effects on their rotarod performance at 6 months, but caused significant (p < 0.05) reduction at 9 and 11 months when compared to control group. Feeding TBZ "late" to WT mice had no apparent effects at 9 months, but caused significant (p < 0.05) reduction at 11 months when compared to control group (Fig 1). Consistent with our previous findings [30], feeding TBZ "early" to YAC128 mice significantly improved (p < 0.05) their rotarod performance at 6, 9, 11 and 13 months when compared to control group of YAC128 mice (Fig 1). Feeding TBZ "late" to YAC128 mice also significantly improved (p < 0.05) rotarod performance of these mice at 9, 11 and 13 months of age when compared to control group of YAC128 mice. However, both YAC128 TBZ feeding groups performed significantly worse (p < 0.05) than any of the WT groups (Fig 1).

Two kinds of beams (11 mm round, and 5 mm square) were used for testing in beam-walking assay. The "latency" and "number of foot slips" were measured for each beam. When results were analyzed, we found that consistent with our previous findings [30], the control group of YAC128 mice (fed with PBS) exhibited a progressive impairment in beam-walking ability (longer beam traverse latencies and increased number of foot slips) with age and beam difficulty compared with control group of WT mice. The significant differences (p < 0.05) between beam performance of control YAC128 and control WT groups were observed at 9, 11 and 13 months of
Feeding TBZ to WT mice had no significant effects on beam performance of these mice (Fig 2A-D). However, feeding TBZ to YAC128 mice improved their beam-walking performance, significantly (\(p < 0.05\)) shortening the latencies and decreasing the foot slip numbers (Fig 2A-D). Significant differences (\(p < 0.05\)) of latency between YAC128 control group and early-TBZ-fed YAC128 group were detected at 9, 11, 13 months of age on 11 mm round beam (Fig 2A, B), and at 6, 9, 11 and 13 months of age on 5 mm square beam (Fig 2C, D). Late-TBZ feeding also significantly (\(p < 0.05\)) improved the beam performance of YAC128 mice at 9, 11 and 13 months of age on both 11 mm round beam (Fig 2A, B) and 5 mm square beam (Fig 2C, D). While conducting beam-walking assays, we noticed that some aging mice exhibited periods of "crawling behavior" (defined as prolonged contact between the thorax and abdomen of the mice and beam surface, with the mice using forelimbs to drag themselves along the beam). Three mice in YAC128 control group crawled on 11 mm round and 5 mm square beams at 11, 13 months time point. In contrast, none of the mice in WT groups or in YAC128 TBZ groups exhibited crawling behavior or fell off the beams at any age tested.

At the conclusion of rotarod and beam-walking behavioral experiments (13 months of age), we also assessed gait abnormalities in all six groups of mice by footprint pattern analysis (Fig 3A). The footprint patterns were assessed quantitatively by five measurements: stride length, hindbase width, frontbase width, front/hind footprint overlap and the ratio of hindbase and forebase as we previously described [30,36]. We found that 13-month-old control YAC128 mice exhibited shorter stride lengths and increased front/hind paw overlap compared with control WT mice (Fig 3B). Feeding TBZ to YAC128 mice improved their stride lengths and overlap (Fig 3B). Our analysis further revealed that, for the hindbase width, Late-feeding TBZ to YAC mice slightly improved when compared with control YAC group (Fig 3B). The frontbase width measurements are similar in all six groups of mice. The ratio of hindbase and forebase showed similar results with hindbase width analysis (Fig 3B).

The combined results from "rotarod" (Fig 1), "beam-walk" (Fig 2), and "gait walk" (Fig 3) behavioral analysis lead us to conclude that both "early" and "late" TBZ feeding significantly alleviates motor deficits developed by aging YAC128 mice.

**Table 1: Design of TBZ trial in YAC128 mice.**

| Group # | Group name          | Number of mice | Mouse genotype | Single dose (50 μl) (three times per week) | Drug dosage (mg/kg) |
|---------|---------------------|----------------|----------------|-------------------------------------------|--------------------|
| 1       | YAC-Ctrl            | 15             | YAC128         | 50 μl PBS                                 | 50 μl PBS          |
| 2       | YAC-TBZ (Early)     | 15             | YAC128         | 0.125 mg of TBZ (started at 2 months of age) | 5 mg TBZ          |
| 3       | YAC-TBZ (Late)      | 15             | YAC128         | 0.125 mg of TBZ (started at 6 months of age) | 5 mg TBZ          |
| 4       | WT-Ctrl             | 15             | WT             | 50 μl PBS                                 | 50 μl PBS          |
| 5       | WT-TBZ (Early)      | 15             | WT             | 0.125 mg of TBZ (started at 2 months of age) | 5 mg TBZ          |
| 6       | WT-TBZ (Late)       | 15             | WT             | 0.125 mg of TBZ (started at 6 months of age) | 5 mg TBZ          |

Six groups of mice were used in our experiments. At 2 months of age, WT and YAC128 mice were divided into three groups each (15 mice in each group, 90 mice total, all females), and drug treatment was initiated. The drugs were fed orally to mice three times a week starting at 2 months of age for early groups and at 6 months of age for late groups. The group number, group name, number and genotype of mice in each group, and dose of single drug treatment (three times/week) are shown for each group. Also shown is the estimated drug dosage in mg/kg. Ctrl, Control; WT, wild type; YAC, YAC128.
YAC128) appear to exhibit some symptoms of depression, such as hypoactivity and immobility in a tail suspension test. We started to observe these behavioral signs at ~7 months of age. We have not observed this phenomenon in the previous study [30]. In the current study we used 1.5-fold higher TBZ dosage compared to the previous study (based on TBZ blood concentration measurements). Also, mice in the current study were fed with TBZ three times per week compare with twice per week in the previous study. In addition, in the previous study we used TBZ + L-Dopa combination and now we used TBZ alone. Most likely all these factors contributed to "depression behavior" observed in the current study and not in the previous study. This "depression phenomenon" is of great interest since many HD patients taking TBZ become severely depressed [32,38]. Thus, we performed formal evaluation of these mice at 11 months of age using Forced-Swim Test (FST) depression behavior paradigm. We found that at 11 months of age YAC128 control group recorded significantly greater FST immobility time than WT control group (Fig 4). These results are consistent with previous description of "depression symptoms" in YAC128 mice using FST and additional behavioral paradigms [39]. We further found that feeding TBZ to WT mice significantly increased time of immobility in FST test (Fig 4). Early TBZ feeding to YAC128 mice resulted in increased time of immobility when compared to control YAC128 mice (Fig 4). Late TBZ feeding to YAC128 mice also increased time of immobility, but had less effect in FST assay than early TBZ feeding (Fig 4).
TBZ protects against striatal cell loss in YAC128 HD mice

To evaluate potential neuroprotective effects of TBZ, at the conclusion of behavioral trail (13 months time point) the brains from all 6 groups of experimental mice were removed from skull and weighted after transcardial perfusion. We found that the brains of control YAC128 mice weighted significantly less \((p < 0.05)\) than the brains of control WT mice group (Fig 5A). Feeding TBZ to WT mice had no significant effect on brain weight of these mice (Fig 5A), whereas feeding TBZ to YAC128 mice resulted in significant increase \((p < 0.05)\) in brain weight of these mice compared with control YAC128 (Fig 5A).

To obtain quantitative information about neuronal loss in these mice, the neuropathological assessments were performed by unbiased stereology as we previously described [30,36]. The brains were fixed, frozen, and sliced with the microtome, and coronal sections corresponding to striatal region were stained with monoclonal antibodies against NeuN protein. Representative NeuN staining of striatal sections from each group of 13-month-old WT and YAC128 mice are shown on Fig 5B. The number of NeuN-positive neurons in the striatum was counted blindly with respect to the nature of the slices (genotype and drug treatment). By stereological analysis, we determined that control YAC128 mice showed significant striatal neuronal loss \((p < 0.05)\) compared with control WT group. Early-TBZ feeding significantly \((p < 0.05)\) improved the beam performance of YAC128 mice at 9, 11 and 13 months of age on both 11 mm and 5 mm beam. Late-TBZ feeding also significantly \((p < 0.05)\) improved the beam performance of YAC128 mice at 9, 11 and 13 months of age on both 11 mm and 5 mm beam.
of YAC128 mice, with both groups showing similar degree of improvement when compared to control YAC128 group (Fig 5A, C). The results of our neuropathological analysis indicated that "early" and "late" feeding with TBZ significantly protected striatal neurons from cell death in aging YAC128 mice.

**Discussion**

Striatum is the predominant target of midbrain dopaminergic neurons [12], and a number of experimental evidence point to a connection between dopamine signaling and MSN neurodegeneration in HD [26]. Striatal MSN neurons expressing dopamine receptors in the striatum predominantly degenerate in HD patients, with cerebral cortex neurons being affected to a much lower extent, and striatal interneurons being spared [40,41]. Biochemical analysis revealed progressive loss of striatal D1 and D2 receptors in post mortem HD brains [42-46]. Imaging studies also reported reduction of striatal D1 and D2 receptors in HD patients [13,14] and in asymptomatic HD mutation carriers [15-19,47,48]. Consistent with analysis of human HD cases, drastic reduction of striatal D1 and D2 receptor density [19,20] and deficiencies in D1 receptor-mediated signaling [21] were observed in R6/2 HD mouse model prior to onset of degeneration. In cellular models dopamine potentiates mutant huntingtin-mediated neurotoxicity by acting via D1-class [30,31] and D2-class [25] dopamine receptors. The HD-like motor dysfunction and selective MSN degeneration have been observed in the dopamine transporter knockout mice [24]. The hyperdopaminergic transmission accelerated formation of Httexp aggregates in 92Q knock-in HD mouse model [29]. In our previous study we reported that feeding L-Dopa to YAC128 mice accelerated progression of the motor phenotype and increased neuronal loss in these mice [30]. Most of these findings are consistent with an idea that dopamine exerts toxic effects on striatal neurons in the context of HD mutation, which leads in compensatory loss of D1 and D2 receptors in striatal region of HD brains.

---

**Figure 3** Gait analysis of WT and YAC128 mice. A. The footprint patterns of 13-month-old YAC128 (YAC) and WT mice. The footprints for control, Early-TBZ, and Late-TBZ groups are shown for both WT and YAC128 mice. B. The footprint patterns were assessed quantitatively by five measurements: stride length, hindbase width, frontbase width, front/hind footprint overlap and the ratio of Hindbase and Forebase. 13-month-old control YAC128 mice exhibited shorter stride lengths and increased front/hind paw overlap compared with control WT mice. Feeding TBZ to YAC mice improved their stride lengths and overlap. For the hindbase width, Late-feeding TBZ to YAC mice improved a little bit compared with control group. The frontbase width measurements are similar for all six groups of mice. The ratio of hindbase and forebase showed similar results with hindbase width analysis. Data for each measure are presented as mean ± SEM. * p < 0.05, significantly different from control YAC128 group.
Striatal MSN loss is the hallmark of HD. Increasing evidence suggested a permissive role of dopaminergic innervation of the striatum in the excitotoxicity in HD. Elevated glutamate-induced Ca$^{2+}$ signals had been found to play an important role in HD [9], and dopamine could significantly potentiate glutamate-induced Ca$^{2+}$ signals and MSN death in HD model [30], suggesting that glutamate and dopamine signaling pathways act synergistically to induce elevated Ca$^{2+}$ signals and to cause apoptosis of HD MSNs [30]. D1 class DARs are coupled to Ca$^{2+}$ signalling via Gs/olf- cAMP-PKA, PKA activation modulates the glutamate-related Ca$^{2+}$ signaling pathway by facilitating the activity of NMDAR [49,50], AMPAR [51], and InsP$_3$R1 [52,53]. D2 class DARs directly coupled to Ca$^{2+}$ signalling in MSNs via PLC activation. Therefore both D1 and D2 DARs might be involved in the potentiation effects of dopamine on elevated Ca$^{2+}$ signalling and cell death in HD MSNs, and blockade of both D1 and D2 DARs would be necessary to exert significantly clinical beneficial effects for dopamine antagonist treatment in HD.

Ca$^{2+}$ signalling is an important downstream in dopamine signalling cascades. In HD MSN, mutant Httexp potentiates the activity of NR2B NMDAR [8,54-57] and InsP$_3$R1 [58], which in turn causes abnormal function and cell death of HD MSN due to the disturbed Ca$^{2+}$ signals. Thus over activation of Ca$^{2+}$ signaling by mutant Httexp may lead to the compensatory loss of D1 and D2 receptors in striatal region of HD brains. Indeed, a significant reduction of striatal D1 and D2 receptors was found in PET imaging studies [13,14] in HD patients and in HD mouse models [19-21]. The idea of the compensatory loss of D1 and D2 receptors are further supported by our recent behavioral evaluation of dopamine tone in aging YAC128 HD mice (Wu at al, in preparation). Decreased density of striatal monoaminergic terminals was found in HD patients using DTBZ ((+)-alpha- [11C]dihydrotetra-benazine) PET imaging technique [59], suggesting the
Figure 5 Neuropathological analysis of WT and YAC128 mice. 

A, Average brain weight of 13-month-old WT and YAC128 (YAC) mice. The brain weight of control YAC128 is significantly reduced compared with control WT group (p < 0.05). The brain weight of YAC128 mice fed with TBZ is significantly increased compared with brain weight of control (Ctrl) YAC128 mice (**p < 0.05).

B, Representative NeuN staining of striatal sections from 13-month-old WT and YAC128 mice.

C, Average striatal neuronal counts of 13-month-old WT and YAC128 mice. Control YAC128 mice showed significant striatal neuronal loss (p < 0.05) compared with control WT mice. YAC128 mice fed with TBZ display significantly increased striatal neuronal counts compared with control YAC128 mice (***p < 0.05) but significantly reduced neuronal counts compared with WT mice (***p < 0.05).

A, C. For each group of mice, the results are shown as mean ± SEM. Ctrl, Control.
Tetrabenazine (TBZ) is a potent blocker of vesicular monoamine transporter (VMAT2). TBZ causes depletion of dopamine content in the presynaptic vesicles and reduction in the dopaminergic tone. In previous clinical trials TBZ has been shown to significantly reduce symptoms in HD patients when compared with placebo group [32-35]. In our previous experiments with YAC128 mouse model we demonstrated that long term administration of TBZ (combined with L-Dopa) alleviated motor deficits and reduced striatal cell loss in these mice [30]. These results indicated that TBZ and possibly other dopamine signaling antagonists may have a therapeutic potential for treatment of HD beyond previously established "symptomatic" benefit. In 2008 TBZ became the first drug officially approved by the Food and Drug administration for treatment of HD patients in the United States [35], greatly enhancing the need to carefully characterize actions of this drug in the context of HD models. We now repeated evaluation of TBZ in YAC128 model of HD and compared "early" (2 months) and "late" (6 months) treatment groups. We found that both "early" and "late" TBZ treatments alleviated the motor deficits (Figs 1, 2 and 3) and reduced striatal cell loss (Fig 5) in YAC128 mice, suggesting that treatment of both presymptomatic and early symptomatic HD patients with TBZ may have neuroprotective effects and delay progression of the disease. We should mentioned here that, TBZ is not a specific dopamine depleting agent, other neurotransmitter innervations such as serotoninergic and some noradrenergic may also play a role in this neuroprotective effects of TBZ.

By blocking VMAT2 TBZ depletes biogenic amines, including dopamine as well as serotonin and norepinephrine. Reduced levels of serotonin can cause depression. Indeed, it has been reported that many HD patients taking TBZ became severely depressed [32,38]. Interestingly, we noticed that TBZ treatment groups of WT and YAC128 mice exhibited some symptoms of depression, such as hypoaactivity and immobility in a tail suspension test. We performed a formal depression behavior analysis at 11 months of age for all 6 groups of mice by using forced-swim test (FST). In this analysis we discovered that both "early" and "late" TBZ treatment groups of WT and YAC128 mice appear to be depressed when compared to control groups (Fig 4). Thus, we concluded that TBZ is a useful therapeutic for treatment of HD, however prolonged treatment with TBZ induces depression. Additional dopamine antagonists which do not interfer with serotonin signaling system should be evaluated as potential HD therapeutics. The paradigms described in the present study can be used for evaluation of beneficial effects of these compounds for HD treatment as well as their ability to cause depression-like behaviors. A novel compound huntexil (pridopidine; ACR16) is a modulator of D2 receptor activity [61,62] which has been recently developed by NeuroSearch for treatment of movement and psychiatric disorders. In recently completed phase III HD clinical trial (MermaiHD study), Huntexil demonstrated significant clinical benefit http://www.neurosearch.com/Default.aspx?ID=16&M=News&PID=12&NewsID=1588

4. Importantly, further analysis of results of phase III trial suggested that Huntexil exerted not only symptomatic benefit but was also able to slow the underlying disease progression http://www.neurosearch.com/Default.aspx?ID=16&M=News&PID=12&NewsID=1589

4. These clinical findings with Huntexil are consistent with disease-modifying effects of TBZ that we observed in the present and previous studies with YAC128 HD mouse model (Fig 5 and [30]). It will be of interest to compare huntexil with TBZ and with other clinically relevant D1 and D2 receptor antagonists in YAC128 mouse model by following procedures described in the present report. Obtained results will provide opportunity to systematically compare symptomatic and disease modifying effects of these dopamine antagonists in HD, as well as evaluate potential side effects such as induction of depression.

Conclusions

Our present study demonstrated that TBZ, a dopamine signaling antagonist have therapeutic potential for treatment of HD beyond previously established "symptomatic" benefit. We found that both "early" and "late" TBZ treatments alleviated the motor deficits and reduced striatal cell loss in YAC128 mice, suggesting that treatment of both presymptomatic and early symptomatic HD patients with TBZ may have neuroprotective effects and delay progression of the disease. Moreover, we have been able to recapitulate and quantify depression-like symptoms in TBZ-treated mice, reminiscent of common side effects observed in HD patients taking TBZ, highlighting the need to develop and evaluate more specific dopamine antagonists for HD treatment.

Methods

Drug delivery in mice

All animal studies were approved by the University of Texas Southwestern Medical Center Animal Care and
Use Committee. YAC128 mice (FVBN/NJ background strain) [37] were obtained from Jackson Labs (stock number 004938). Age-matched female wild type and YAC128 hemizygous littermate mice were used in all our experiments. Tetrabenazine (TBZ) was obtained from Tocris, mixed with 2% cornflour using ceramic grinder and resuspended in PBS. TBZ was delivered to mice by oral feeding approach that we used in our previous studies with YAC128 mice [30]. The drugs were fed orally to mice three times a week starting at 2 months of age. The mice were fed with 0.125 mg of TBZ suspended in 50 μl of PBS with 2% corn flour. To determine the efficacy of this drug delivery procedure, 7 wild-type mice of 2 months of age were fed orally with 0.125 mg of TBZ formulation and the blood samples were collected 30 minutes after drug feeding. The samples were diluted 1:1 in water for hemolysis, flash frozen and shipped to Melior Discovery (Exton, PA) for quantitative analysis. The TBZ levels were analyzed using HPLC and compared with a standard TBZ sample. Data are expressed as average of the values from five samples ± SEM (see Results).

Motor coordination assessments in mice

The motor coordination experiments were performed as previously described [30,36] with minor modifications. The “beam-walking” assay was performed using a home-built experimental setup. The 17 mm round beam, 11 mm round beam, and 5 mm square beam were used for training. At each time point (2, 6, 9, 11 and 13 months of age), the mice were trained to traverse the beam to the enclosed box. The mice were trained on 17 mm round beam for the 1st day, 11 mm round beam for the 2nd day, and 5 mm square beams for the 3rd day (two trials per day). Once the stable baseline of performance was obtained, the mice were tested in two consecutive trials on 11 mm round beam and then on 5 mm square beam, in each case progressing from the widest to the narrowest beam. The latency to traverse the middle section (80 cm in length) of each beam and the number of times the hind feet slipped off each beam were recorded for each trial. For each measurement, the mean scores of the two trials for each beam were used in the analysis.

The rotarod assessments were performed using Econox rotarod apparatus (Columbus Instruments, Columbus, OH) as previously described [30]. At each time point, the mice were trained on the accelerating rotarod (accelerated from 0 to 40 rpm over 200 s) with 2 trials per day for 3 consecutive days, by which time a steady baseline level of performance was attained. The testing was executed over 1 day with 1.5 h of rest between tests. The mean latency to fall off the rotarod recorded in the two trials is used in analysis.

For the footprint test, the forepaws and hindpaws of the mice were coated with red and green nontoxic paints, respectively. The mice were trained to walk along a 50-cm-long, 10-cm-wide, paper-covered runway (with 10-cm-high walls) into an enclosed box. All the mice were given two runs per day for 3 consecutive days. A fresh sheet of white paper was placed on the floor of the runway for each run. The footprint patterns were assessed quantitatively by five measurements: stride length, hindbase width, frontbase width, front/hind footprint overlap and the ratio of hindbase and forebase as we previously described [30].

Forced swim test

Immobility in the forced swim test (FST) is a commonly used for measurement of depression in rodents [63-65]. Mice were individually placed into an individual glass beaker (54 cm in height and 24 cm in diameter) filled with room temperature water (23-25°C) to 40 cm depth. All test sessions were recorded for a total of 300 seconds by a video camera from the side of the cylinder. Total immobility time of each mouse after the first 120 seconds was manually scored by an experienced experimenter who was blinded to the genotype and drug treatment of the mice. Immobility was defined as the state in which mice were judged to be making only the movements necessary to keep their head above the surface.

Neuropathological assessments in mice

The neuropathological assessments were performed as previously described [30]. At conclusion of behavioral testing (13 months time point), the mice were terminally anesthetized and perfused transcardially with 10 ml of 0.9% saline followed by 100 ml of fixative (4% paraformaldehyde in 0.1 M PBS, pH 7.4). All brains were removed from the skull, weighed, and transferred to postfixative overnight at 4°C in 4% paraformaldehyde and equilibrated in 20-30% (w/v) sucrose in PBS. The brains were processed and cut into 30-μm-thick coronal sections as described above. The coronal sections spaced 360 μm apart throughout the striatum (in the range from +1.70 mm to -2.30 mm relative to bregma) were stained with NeuN monoclonal antibody (1:1000 dilution; Millipore, Billerica, MA) and biotinylated anti-mouse secondary antibodies (1:200 dilution; Vector Laboratories, Burlington, Ontario, Canada) (M.O.M kit). Signal was amplified with an ABC Elite kit (Vector Laboratories) and detected with diaminobenzidine (Vector Laboratories). All quantitative stereological analyses were performed blindly with respect to the nature of slices (genotype and drug feeding) using Stereoinvestigator setup and software (MicroBrightField, Williston, VT). The grid size was set to 450 × 450 μm, and the counting frame was 50 × 50 μm. The average slice thickness after histological processing was determined to be 25 μm.
Statistical data analysis
The data were analyzed using SAS 9.13. The rotaror performance and beam-working performance were analyzed using 3 way ANOVA accounting for gene type (YAC128 vs wild type), drug treatment (PBS vs Early or Late-TBZ feeding) and animals age for all factor analysis, 2 way ANOVA for comparing treatment effects of Early or Late-TBZ feeding vs PBS control, or Early or Late-TBZ feeding in YAC128 and WT respectively, and 1 way ANOVA for age effects in animals treated with PBS alone. Tukey test or Student t test were also used where applicable.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
HM designed the study, participated in the experiments, performed the statistical analysis and wrote the manuscript. XC and YL participated in the behavioral study and neuropathological analysis. IB and TST conceived of the study, participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Acknowledgements
We thank Xiangmei Kong for help with maintaining the YAC128 mouse colony and behavioral experiments, Leah Benson and Janet Young for administrative assistance, Shari Birnbaum for advice on forced swimming test experiments. IB is a holder of Carla Cocke Francis Professorship in Alzheimer’s Research and supported by the CHDI foundation and NINDS R01 NS056624. TST is supported by the Knowledge Innovation Program of CAS, KSCX2-YW-R-148 and NSFC30970931.

Author Details
1Department of Physiology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390, USA and State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Chinese Academy of Sciences, 1 Beichen West Road, Chaoyang District, Beijing 100101, PR China

Received: 31 December 2009 Accepted: 26 April 2010 Published: 26 April 2010

References
1. MacDonald ME, Huntington: alive and well and working in middle management. Sci STKE 2003, 2003pe48.
2. Vonsattel JP, DiFiglia M: Huntington disease. J Neuropathol Exp Neurol 1998, 57:369-384.
3. The Huntington’s Disease Collaborative Research Group: A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 1993, 72:971-983.
4. Tobin AJ, Sigier ER: Huntington’s disease: the challenge for cell biologists. Trends Cell Biol 2000, 10:531-536.
5. Ross CA: Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington’s disease and related disorders. Neuron 2002, 35:819-822.
6. Harjes P, Wanker EE: The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem Sci 2003, 28:425-433.
7. Sugar RL, Rubinstein DC: Transcriptional abnormalities in Huntington disease. Trends Genet 2003, 19:233-238.
8. Zeroun MM, Fernandes HB, Krebs C, Shehade J, Wellington CL, Leavitt BR, Bainbridge KG, Hayden MR, Raymond LA: Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsically apoptotic pathway in YAC transgenic mouse model of Huntington’s disease. Mol Cell Neurosci 2004, 25:469-479.
9. Tang TS, Slew EJ, Luu V, Stavrevskaia IG, Sugimoto M, Llinas R, Kristal BS, Hayden MR: Bezpoxrevzyn: I. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington’s disease. Proc Natl Acad Sci USA 2005, 102:2602-2607.
10. Shehadeh J, Fernandes HB, Zeron Mullins MM, Graham RK, Leavitt BR, Hayden MR, Raymond LA: Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease. Neurobiol Dis 2006, 21:592-403.
11. Bezpoxrevzyn I: Calcium signaling and neurodegenerative diseases. Trends Mol Med 2009, 15:869-900.
12. Gerfen CR: The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci 1992, 15:133-139.
13. Sedvall G, Karlsson P, Lundin A, Anvert M, Suhara T, Hallcl M, Farde L: Dopamine D1 receptor number—a sensitive PET marker for early brain degeneration in Huntington’s disease. Eur Arch Psychiatry Clin Neurosci 1994, 243:249-255.
14. Turjanski N, Weeks R, Dolan R, Harding AE, Brooks DJ: Striatal D1 and D2 receptor binding in patients with Huntington’s disease and other choreas. A PET study Brain 1995, 118(Pt 6):689-696.
15. Antonini A, Leenders KL, Spiegel R, Meier D, Anvert M, Sanchez-Pernaute R, de Yebe sne JG, Boesiger P, Weindl A, Maguire RP: Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington’s disease. Brain 1996, 119(Pt 6):2085-2095.
16. Weeks RA, Picconi P, Harding AE, Brooks DJ: Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington’s disease. Ann Neurol 1996, 40:49-54.
17. Ginovart N, Lundin A, Farde L, Hallcl M, Backman C, Swahn CG, Pauli S, Sedvall G: PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington’s disease. Brain 1997, 120(Pt 3):503-514.
18. Backman L, Robins-Wahlin TB, Lundin A, Ginovart N, Farde L: Cognitive deficits in Huntington’s disease are predicted by dopaminergic PET markers and brain volumes. Brain 1997, 120(Pt 12):2207-2217.
19. Cha JH, Kosinski CM, Kemner JA, Alisofa SA, Mangiarini L, Davies SW, Penney JB, Bates GP, Young A2: Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc Natl Acad Sci USA 1998, 95:6480-6485.
20. Ariano MA, Aironin N, Difiglia M, Tagle DA, Sibley DR, Leavitt BR, Hayden MR, Levine MS: Striatal neurochemical changes in transgenic models of Huntington’s disease. J Neurosci Res 2002, 68:716-729.
21. Bibb JA, Yan Z, Smillingson P, Snyder GL, Pieribone VA, Horuchi A, Nairn AC, Messer A, Greengard P: Severe deficiencies in dopamine signaling in presymptomatic Huntington’s disease mice. Proc Natl Acad Sci USA 2000, 97:6809-6814.
22. Petersen A, Puschan Z, Larkus hia J, NiciNicoliak B, Wielkop P, O’Connor WT, Brundin P: Evidence for dysfunction of the nigrostriatal pathway in the R6/1 line of transgenic Huntington’s disease mice. Neurobiol Dis 2002, 13:134-146.
23. Zhuang X, Oosting RS, Jones SR, Gainetdinov RR, Miller GW, Caron MG, Hen R: Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc Natl Acad Sci USA 2001, 98:1982-1987.
24. Cyr M, Beaulieu JM, Laakso A, Sotnikova TD, Yao WD, Bohn LM, Gainetdinov RR, Caron MG: Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. Proc Natl Acad Sci USA 2003, 100:11035-11040.
25. Charvin D, Vanhoutte P, Pages C, Borelli E, Cabezeco J: Unraveling a role for dopamine in Huntington’s disease: the dual role of reactive oxygen species and D2 receptor stimulation. Proc Natl Acad Sci USA 2005, 102:12218-12223.
26. Jakel RJ, Marages WF: Neuronal cell death in Huntington’s disease: a potential role for dopamine. Trends Neurosci 2000, 23:239-245.
27. Wersinger C, Chen J, Siddique A: Bimodal induction of dopamine-mediated striatal neurotoxicity is mediated through both activation of D1 dopamine receptors and autodiation. Mol Cell Neurosci 2004, 25:124-137.
28. Benchooa A, Tricoulier Y, Diguous E, Malgorn C, Gaillard MC, Dufour N, Elalouf JM, Krajewski S, Hantraye P, Delegon N, Brouillet E: Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II. Hum Mol Genet 2008, 17:1446-1456.
29. Cyr M, Sotnikova TD, Gainetdinov RR, Caron MG: Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin. Faseb J 2006, 20:2541-2543.
30. Tang TS, Chen X, Liu J, Bezprozvanny I: Dopaminergic signaling and striatal neurodegeneration in Huntington’s disease. J Neurosci 2007, 27:7890-7910.

31. Paolotti P, Vila R, Rife M, Lizzano JM, Alberch J, Gines S: Dopaminergic and glutamatergic signaling crosstalk in Huntington’s disease neurodegeneration: the role of p25/cyclin-dependent kinase S. J Neurosci 2008, 28:10090-10101.

32. Huntington Support Group: Tetraabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006, 66:366-372.

33. Kenney C, Hunter C, Jankovic J: Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007, 22:193-197.

34. Kenney C, Jankovic J: Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother 2006, 6:7-17.

35. Hayden MR, Leavitt BR, Yacowen U, Kirkpatrick P: Tetrabenazine. Nat Rev Drug Discov 2009, 8:17-18.

36. Tang TS, Guo C, Wang H, Chen X, Bezprozvanny I: Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington’s disease mouse model. J Neurosci 2009, 29:127-1266.

37. Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y, Oh R, Bissada N, Hessam SM, Yang YZ, et al.: Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 2003, 12:1555-1567.

38. Kenney C, Hunter C, Meja N, Jankovic J: Is history of depression a contraindication to treatment with tetrabenazine? Clin Neuropharmacol 2006, 29:259-264.

39. Pouladi MA, Graham RK, Karasinska JM, Xie Y, Santos RD, Petersen A, Wang H, Chen X, Bezprozvanny I: The pattern of neurodegeneration in Huntington’s disease mice. Neurosci 2007, 143:261-263.

40. Tang TS, Guo C, Wang H, Chen X, Bezprozvanny I: Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington’s disease mouse model. J Neurosci 2009, 29:127-1266.

41. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr: Comparison with traditional synaptic markers.

42. Pickup J, Hafner M, Braden SK, Kees C, Bohnen NI, Koeppe RA, Meyer P, Ficaro EP, et al.: Decreased striatal monoaminergic terminals in Huntington disease mouse model. J Neurosci 2006, 26:1651-1663.

43. Glass M, Dragunow M, Faull RL: The pattern of neurodegeneration in Huntington’s disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington’s disease. Neuroscience 2000, 97:505-519.

44. Richfield EC, O’Brien JF, Egnathius JD, de Souza JD, Yang YZ, Oh R, Bissada N, Hessam SM, Yang YZ, et al.: Heterogeneous dopaminergic receptor changes in early and late Huntington’s disease. Neurosci Lett 1991, 132:121-126.

45. Filouz F, Wagster MV, Falstein S, Price DL, Hedreen JC, Dawson TM, Wamsley JK: Nigral dopaminergic type-1 receptors are reduced in Huntington’s disease: a postmortem autoradiographic study using [3H]SCH 23390 and correlation with [3H]Forskolin binding. Exp Neurol 1990, 110:219-227.

46. Joyce JN, Lexow N, Bird E, Winokur A: Organization of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in Huntington’s and schizophrenia. Synapse 1988, 25:46-557.

47. Andrews TC, Weeks RA, Turjanski N, Gunn RN, Watkins LH, Sahakian B, Hodges JR, Rosser AE, Wood NW, Brookes DJ: Huntington’s disease progression. Brain 1999, 122:235-2363.

48. Luthi-Carter R, Strand A, Peters NL, Solano SM, Hollingsworth ZR, Menon AS, Frey AS, Pektor BS, Penney EB, Schilling G, et al.: Decreased expression of striatal signaling genes in a mouse model of Huntington’s disease. Hum Mol Genet 2000, 9:1259-1271.

49. Levine MS, Attemus KL, Cepeda C, Cromwell HC, Crawford C, Ariano MA, Dragjo I, Sibley DR, Wetzelph H: Modulatory actions of dopamine on NMDA receptor-mediated responses are reduced in D1A-deficient mutant mice. J Neurosci 1996, 16:5870-5882.

50. Flores-Hernandez J, Cepeda C, Hernandez-Echeagaray E, Calvert CR, Jokel ES, Fienberg AA, Greengard P, Levine MS: Dopamine enhancement of NMDA currents in dissociated medium-sized striatal neurons: role of D1 receptors and DARPP-32. J Neurophysiol 2002, 88:3010-3020.

51. Yan Z, Hsieh-Wilson L, Feng J, Tomizawa K, Allen PB, Fienberg AA, Nairn AC, Greengard P: Protein phosphatase 1 modulation of neostriatal AMPA channels: regulation by DARPP-32 and spinophilin. Nat Neurosci 1999, 2:13-17.

52. Tang TS, Tu H, Wang Z, Bezprozvanny I: Modulation of type 1 inositol (1,4,5)-trisphosphate receptor function by protein kinase A and protein phosphatase type 1. J Neurosci 2003, 23:403-415.

53. Tang TS, Bezprozvanny I: Dopamine receptor-mediated Ca2+ signaling in striatal medium spiny neurons. J Biol Chem 2004, 279:42082-42094.

54. Chen N, Luo T, Wellington C, Metzler M, McCutcheon K, Hayden MR, Raymond LA: Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin. J Neurochem 1999, 72:1890-1898.

55. Song C, Zhang Y, Parsons CG, Liu YF: Expression of polyglutamine-expanded huntingtin induces tyrosine phosphorylation of N-methyl-D-aspartate receptors. J Biol Chem 2003, 278:33364-33369.

56. Sun Y, Savanenin A, Reddy PH, Liu YF: Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J Biol Chem 2001, 276:24713-24718.

57. Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Blundin P, Hayden MR, Raymond LA: Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington’s disease. Neurology 2002, 58:8849-8860.

58. Tang T-S, Tu H, Chan EY, Maximov A, Wang Z, Wellington CL, Hayden MR, Bezprozvanny I: Huntington and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) trisphosphate receptor type 1. Neurology 2003, 9:227-239.

59. Bohnen NI, Koeppe RA, Meyer P, Frey KA, Ficaro EP, Wernette K, Kilbourn MR, Kuhl DE, Frey KA, Albin RL: Decreased striatal monoaminergic terminals in Huntington disease. Neurology 2000, 54:1753-1759.

60. Bohnen NI, Frey KA. The role of positron emission tomography imaging in movement disorders. Neuroimaging Clin N Am 2003, 13:791-803.

61. Rung JP, Rung E, Helgeson L, Johansson AM, Svensson K, Carlsson A, Svenningsen MS, Carlsson A. Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization. J Neural Transm 2006, 115:899-908.

62. Tadros Y, Kitagawa H, Forbes RA, McQuade RD, Stark A, Kikuchi T: Differences in agonist/antagonist properties at human dopamine D2 receptors between aripiprazole, bifeprunox and SD8 208-912. Eur J Pharmacol 2007, 574:103-111.

63. Cryan JF, Markou A, Lucki I: Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002, 23:238-245.

64. Porsolt RD, Anto RG, Blavet N, Jalfre M: Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 1978, 47:39-391.

65. Porsolt RD, Le Pichon M, Jalfre M: Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.